Clinical Financial Services (CFS) Launches New Service to Streamline Clinical Trial Activation
As part of its ongoing mission to provide comprehensive business and financial management solutions in support of clinical trials, Clinical Financial Services (CFS) is pleased to announce the launch of its newest offering, Site Activation Services. This new service, which includes regulatory document collection and management as well as global investigator budget and contract management, will streamline and automate the trial activation process and minimize financial risk for clinical trial sponsors, CROs, and investigative sites.
Headed by a team dedicated to managing the complex tasks required to activate investigator sites, CFS can accelerate clinical trial cycle times by maximizing the number of sites that are activated and "enrollment ready" when the enrollment phase of the trial begins.
- By pre-populating regulatory and financial disclosure documents with data from an enterprise-wide proprietary database, CFS ensures the accuracy of site and investigator information, prevents redundancy and speeds the time it takes to complete this paperwork.
- Through extensive audit capabilities, CFS ensures that financial disclosure information is compliant with 21CFR Part 54 and internal SOPs, consistent with Form FDA 1572 and aligned with aggregate spend payment data.
- With a global legal network operating in more than 60 countries, CFS supports complex contract negotiations around the world.
- By offering a technologically advanced project dashboard that is available 24/7, CFS offers unprecedented visibility into the status of every trial start-up document.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
